Reviewed,
UniProtKB/Swiss-Prot Q13740 (CD166_HUMAN)
Last modified
July 22, 2008.
Version 80.
History...
Clusters with 100%,
90%,
50% identity |
Documents (8) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: CD166 antigen Alternative name(s): Activated leukocyte cell adhesion molecule CD_antigen=CD166 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 583 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Cell adhesion molecule that binds to CD6. Involved in neurite extension by neurons via heterophilic and homophilic interactions. May play a role in the binding of T- and B-cells to activated leukocytes, as well as in interactions between cells of the nervous system. |
| Subcellular location | |
| Tissue specificity | Spleen, placenta, liver, and weakly in liver. Expressed by activated T-cells, B-cells, monocytes and thymic epithelial cells. Expressed by neurons in the brain. Restricted expression in tumor cell lines. Preferentially expressed in highly metastasizing melanoma cell lines. |
| Domain | The CD6 binding site is located in the N-terminal Ig-like domain. |
| Sequence similarities | Contains 3 Ig-like C2-type (immunoglobulin-like) domains. Contains 2 Ig-like V-type (immunoglobulin-like) domains. |
Ontologies
Keywords | |
|---|---|
| Biological process | Cell adhesion |
| Cellular component | Membrane |
| Coding sequence diversity | Alternative splicing Polymorphism |
| Domain | Immunoglobulin domain Repeat Signal Transmembrane |
| PTM | Glycoprotein |
| Technical term | 3D-structure Direct protein sequencing |
Gene Ontology (GO) | |
| Biological process | cell adhesion Ref.1 Traceable author statement. Source: ProtInc signal transduction Ref.1Traceable author statement. Source: ProtInc |
| Molecular function | receptor binding Ref.1 Traceable author statement. Source: ProtInc |
| Complete GO annotation... | |
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] | |||||
| Isoform 1 (identifier: Q13740-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | |||||
| Isoform 2 (identifier: Q13740-2) The sequence of this isoform differs from the canonical sequence as follows: 503-515: Missing. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | ||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 27 | 27 | Potential | |||||||||||||||||||||||
| Chain | 28 – 583 | 556 | CD166 antigen | |||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||
| Topological domain | 28 – 527 | 500 | Extracellular Potential | |||||||||||||||||||||||
| Transmembrane | 528 – 549 | 22 | Potential | |||||||||||||||||||||||
| Topological domain | 550 – 583 | 34 | Cytoplasmic Potential | |||||||||||||||||||||||
| Domain | 28 – 120 | 93 | Ig-like V-type 1 | |||||||||||||||||||||||
| Domain | 125 – 234 | 110 | Ig-like V-type 2 | |||||||||||||||||||||||
| Domain | 245 – 328 | 84 | Ig-like C2-type 1 | |||||||||||||||||||||||
| Domain | 333 – 409 | 77 | Ig-like C2-type 2 | |||||||||||||||||||||||
| Domain | 416 – 501 | 86 | Ig-like C2-type 3 | |||||||||||||||||||||||
Amino acid modifications | ||||||||||||||||||||||||||
| Glycosylation | 91 | 1 | N-linked (GlcNAc...) | |||||||||||||||||||||||
| Glycosylation | 95 | 1 | N-linked (GlcNAc...) | |||||||||||||||||||||||
| Glycosylation | 167 | 1 | N-linked (GlcNAc...) | |||||||||||||||||||||||
| Glycosylation | 265 | 1 | N-linked (GlcNAc...) | |||||||||||||||||||||||
| Glycosylation | 306 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||
| Glycosylation | 361 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||
| Glycosylation | 457 | 1 | N-linked (GlcNAc...) Potential | |||||||||||||||||||||||
| Glycosylation | 480 | 1 | N-linked (GlcNAc...) | |||||||||||||||||||||||
| Glycosylation | 499 | 1 | N-linked (GlcNAc...) | |||||||||||||||||||||||
| Disulfide bond | 43 ↔ 113 | Potential | ||||||||||||||||||||||||
| Disulfide bond | 157 ↔ 220 | Potential | ||||||||||||||||||||||||
| Disulfide bond | 270 ↔ 313 | Potential | ||||||||||||||||||||||||
| Disulfide bond | 354 ↔ 392 | Potential | ||||||||||||||||||||||||
| Disulfide bond | 435 ↔ 485 | Potential | ||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||
| Alternative sequence | 503 – 515 | 13 | Missing in isoform 2. | |||||||||||||||||||||||
| Natural variant | 229 | 1 | G → D: dbSNP rs10933819. | |||||||||||||||||||||||
| Natural variant | 258 | 1 | N → S: dbSNP rs1044240. | |||||||||||||||||||||||
| Natural variant | 301 | 1 | T → M: dbSNP rs1044243. | |||||||||||||||||||||||
| Natural variant | 315 | 1 | L → M: dbSNP rs12629872. | |||||||||||||||||||||||
| Natural variant | 352 | 1 | V → M: dbSNP rs2291375. | |||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||
| Sequence conflict | 516 | 1 | D → N in ABF48405. Ref.2 | |||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||
| Beta strand | 39 – 44 | 6 | ||||||||||||||||||||||||
| Beta strand | 51 – 59 | 9 | ||||||||||||||||||||||||
| Beta strand | 65 – 71 | 7 | ||||||||||||||||||||||||
| Beta strand | 76 – 80 | 5 | ||||||||||||||||||||||||
| Beta strand | 86 – 90 | 5 | ||||||||||||||||||||||||
| Beta strand | 92 – 102 | 11 | ||||||||||||||||||||||||
| Beta strand | 105 – 107 | 3 | ||||||||||||||||||||||||
| Beta strand | 109 – 117 | 9 | ||||||||||||||||||||||||
| Beta strand | 120 – 123 | 4 | ||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand." Bowen M.A., Patel D.D., Li X., Modrell B., Malacko A.R., Wang W.-C., Marquardt H., Neubauer M., Pesando J.M., Francke U., Haynes B.F., Aruffo A. J. Exp. Med. 181:2213-2220(1995) [PubMed: 7760007] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT MET-301, PARTIAL PROTEIN SEQUENCE. |
| [2] | "A novel alternatively spliced variant of activated leukocyte cell adhesion molecule (ALCAM/CD166) resulting from a deletion in the extracellular membrane proximal stem." Abe Y., Bui-Thanh N.-A., Smith C.W., Ballantyne C.M., Burns A.R. Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2). |
| [3] | "MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule)." Degen W.G., van Kempen L.C., Gijzen E.G., van Groningen J.J., van Kooyk Y., Bloemers H.P.J., Swart G.W. Am. J. Pathol. 152:805-813(1998) [PubMed: 9502422] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 2-583 (ISOFORM 1), TISSUE SPECIFICITY. |
| [4] | "Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM." Skonier J.E., Bowen M.A., Emswiler J., Aruffo A., Bajorath J. Biochemistry 35:12287-12291(1996) [PubMed: 8823162] [Abstract] Cited for: DOMAIN CD6 BINDING. |
| [5] | "Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry." Zhang H., Li X.-J., Martin D.B., Aebersold R. Nat. Biotechnol. 21:660-666(2003) [PubMed: 12754519] [Abstract] Cited for: GLYCOSYLATION AT ASN-91; ASN-167; ASN-480 AND ASN-499. |
| [6] | "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry." Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D. J. Proteome Res. 4:2070-2080(2005) [PubMed: 16335952] [Abstract] Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-95; ASN-265 AND ASN-499, MASS SPECTROMETRY. Tissue: Plasma. |
| [7] | "Molecular model of the N-terminal receptor-binding domain of the human CD6 ligand ALCAM." Bajorath J., Bowen M.A., Aruffo A. Protein Sci. 4:1644-1647(1995) [PubMed: 8520490] [Abstract] Cited for: 3D-STRUCTURE MODELING OF 28-133. |
Cross-references
Sequence databases | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L38608 mRNA. Translation: AAB59499.1. DQ486139 mRNA. Translation: ABF48405.1. DQ486140 mRNA. Translation: ABF48406.1. Y10183 mRNA. Translation: CAA71256.1. | |||||||||||||
| PIR | I39428. | ||||||||||||
| RefSeq | NP_001618.2. | ||||||||||||
| UniGene | Hs.591293 | ||||||||||||
3D structure databases | |||||||||||||
| |||||||||||||
| ModBase | Search... | ||||||||||||
Protein-protein interaction databases | |||||||||||||
| IntAct | Q13740. | ||||||||||||
PTM databases | |||||||||||||
| PhosphoSite | Q13740. | ||||||||||||
Genome annotation databases | |||||||||||||
| Ensembl | ENSG00000170017. Homo sapiens. [Contig view] | ||||||||||||
| GeneID | 214. | ||||||||||||
| KEGG | hsa:214. | ||||||||||||
Organism-specific databases | |||||||||||||
| H-InvDB | HIX0003517. | ||||||||||||
| HGNC | HGNC:400. ALCAM. | ||||||||||||
| HPA | CAB002148. HPA010926. | ||||||||||||
| MIM | 601662. gene. | ||||||||||||
| PharmGKB | PA24691. | ||||||||||||
| GenAtlas | Search... | ||||||||||||
| GeneCards | Search... | ||||||||||||
| GeneLynx | Search... | ||||||||||||
Phylogenomic databases | |||||||||||||
| HOGENOM | Q13740. | ||||||||||||
| HOVERGEN | Q13740. | ||||||||||||
Gene expression databases | |||||||||||||
| ArrayExpress | Q13740. | ||||||||||||
| CleanEx | HS_ALCAM. | ||||||||||||
Family and domain databases | |||||||||||||
| InterPro | IPR013162. CD80_C2-set. IPR013151. Ig. IPR007110. Ig-like. IPR013783. Ig-like_fold. IPR003006. Ig/MHC_CS. IPR003599. Ig_sub. [Graphical view] | ||||||||||||
| Gene3D | G3DSA:2.60.40.10. Ig-like_fold. 3 hits. | ||||||||||||
| Pfam | PF08205. C2-set_2. 1 hit. PF00047. ig. 1 hit. [Graphical view] | ||||||||||||
| SMART | SM00409. IG. 3 hits. [Graphical view] | ||||||||||||
| PROSITE | PS50835. IG_LIKE. 4 hits. [Graphical view] | ||||||||||||
| ProDom | Q13740. [Graphical view] [Entries sharing at least one domain] | ||||||||||||
| BLOCKS | Search... | ||||||||||||
Other Resources | |||||||||||||
| SOURCE | Search... | ||||||||||||
| ProtoNet | Search... | ||||||||||||
Entry information
| Entry name | CD166_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q13740 Secondary accession number(s): O60892, Q1HGM8, Q1HGM9 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation project | HPI (Human Proteome Initiative) | ||||||||
Relevant documents
| Human cell differentiation molecules CD nomenclature of surface proteins of human leucocytes and list of entries |
| Human chromosome 3 Human chromosome 3: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| UniProtKB secondary accession numbers Index of UniProtKB secondary accession numbers |
| SIMILARITY comments Index of protein domains and families |

Clusters with


